NBRV Research and Charts

NBRV - Nabriva Therapeutics PLC (Healthcare: Biotechnology)

Projected Earnings Date: 2023-11-12 (Delayed quote data 2025-01-02)

Last 0.00	Change ⇓ 0.00 (0.00%)	Volume 415
	Open 0.00	High 0.00	Low 0.00

8EMA (Daily) 0.00	40EMA (Daily) 0.00	50EMA (Daily) 0.00	STO (Daily) 0.000	MACD Hist (Daily) 0.000
8EMA (Weekly) 0.000	40EMA (Weekly) 0.10	50EMA (Weekly) 0.28	STO (Weekly) 0.000	MACD Hist (Weekly) 0.026


Company Profile
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.